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Abstract 
 
Objectives:  
This report summarizes the 5-year clinical and haemodynamic data from three 
prospective, European multicenter trials with the Perceval suture-less aortic 
valve. 
 
Methods: 
From 4/2007 to 8/2012, 731 consecutive patients (mean age 78.5 years; 68.1% 
females; mean logistic EuroScore 10.9%) underwent AVR with the Perceval 
valve in 25 European centers. Isolated AVR was performed in 498 (68.1%) 
patients. Minimally invasive approach was performed in 189 (25.9%) cases. 
Cumulative follow- up was 729 patients-year. 
 
Results:  
In isolated AVR, mean cross-clamp and CPB times were 30.8 and 50.8 min in 
full sternotomy, and 37.6 and 64.4 min in minimally invasive approach, 
respectively. 
Early Cardiac-related deaths occurred in 1.9%. Overall survival at 1 and 5 years 
were 92.1% and 74.7%, respectively. 
Major paravalvular leak occurred in the 1.4% (early) and 1% (late follow up), 
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respectively.  Significant improvement in clinical status was observed 
postoperatively in the majority of patients.  
Mean and peak gradients decreased from 42.9 and 74.0 mmHg preoperatively, 
to 7.8 and 16 mmHg at 3-year follow-up. LV-mass decreased from 254.5 g to 
177.4 g at 3 years.  
 
Conclusions:  
This European multi-center experience with largest cohort of patients with 
sutureless valves till date, shows excellent clinical and haemodynamic results 
that remain stable even up to 5 years follow-up. Even in this elderly patient 
cohort with 40% octogenarians, both early and late mortality were very low. 
There were no valve migrations, structural valve degeneration and valve 
thrombosis in follow-up. 
The sutureless technique is a promising alternative to biological AVR. 
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Introduction 
Aortic valve replacement (AVR) is the accepted ‘Gold Standard’ for the 
treatment of severe or symptomatic aortic valve stenosis. Due to increasing age 
of the patient population (reflecting the demographic changes) in the western 
world, the use of biological valves has increased over the past years. At the 
same time, a large proportion of these patients require concomitant surgical 
procedures in addition to AVR [1]. 
Although trans-apical or trans-femoral aortic valve implantations (TAVI) have 
been introduced for high risk patients, they are limited to patients with isolated 
aortic valve pathology [2].  
 
Three consecutive European, multicenter, prospective, non-randomized clinical 
trials (Pilot, Pivotal, and CAVALIER) were designed to evaluate the sutureless 
Perceval aortic valve prosthesis in elderly patients. The Perceval valve (Sorin 
Group, Saluggia, Italy) is a bioprosthetic heart valve made of bovine 
pericardium allowing for a fast implantation through a sutureless technique. We 
describe the combined results of these three consecutive trials. 
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Material and Methods 
 
Study design 
 
This series comprises the cumulative results of patients undergoing aortic valve 
replacement with or without concomitant procedures from three consecutive 
European prospective multicenter trials (Pilot, Pivotal and CAVALIER), between 
2007 and 2012.  
 
25 centers in 8 European countries took part in these three studies. Approval 
for these studies was granted by the Ethical Committees of the Hospitals 
involved and each patient gave signed informed consent before being enrolled 
in the trials. 
 
Perceval Pilot trial  
The objective of the Pilot trial was to assess the safety of aortic valve 
replacement with the sutureless Perceval valve in 30 symptomatic patients, 
aged 75 and older. The primary endpoint was the assessment of the safety of 
the Perceval prosthesis in terms of mortality and morbidity at 30 days, 
correlated to prosthetic valve performance. Secondary endpoints were the 
evaluation of mortality and morbidity, the evaluation of the clinical status on the 
basis of the New York Heart Association (NYHA) functional classification, and 
the evaluation of the haemodynamic performance at 1, 3, 6 and 12 months from 
implantation, respectively. 
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Perceval Pivotal trial  
The primary objective of the Pivotal study was to assess the performance of the 
Perceval valve at 3 to 6 months after implantation in 150 high surgical risk 
patients aged ≥75 years, requiring surgical intervention to replace the aortic 
valve. The primary endpoint was the assessment of the Perceval prosthesis 
safety and performance at 3 to 6 months after surgery. Secondary endpoints 
included the evaluation of the Perceval valve in terms of improvement of clinical 
status, haemodynamic performance by echocardiography, and assessment of 
mortality and morbidity rates at discharge and 12 months after implant, 
respectively. 
 
These two Perceval trials aimed at obtaining initial CE mark approval, even 
though only two prosthesis sizes (Size S and Size M) were available. The 
outcomes showed adequate safety and performance, and allowed the Perceval 
to obtain CE mark in January 2011 (for sizes S and M) under limited indications. 
 
CAVALIER trial 
The CAVALIER trial was designed to assess the safety and effectiveness of the 
Perceval valve at 12 months after implantation when used to replace a 
diseased or dysfunctional aortic valve or aortic valve prosthesis in patients older 
than 65 years. The primary endpoint was the evaluation of the safety (assessed 
in terms of mortality and morbidity) and effectiveness (assessed in terms of 
improvement of clinical status as well as haemodynamic performance) of the 
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Perceval valve at 12 months after the implants. The secondary endpoints of the 
clinical investigation were the assessment of safety and effectiveness at 
discharge and 3 to 6 months after surgery and yearly thereafter. Besides 
lowering the age limit to younger patients (65 years or older), this study included 
two additional prosthesis sizes: Size L (from February 2010) and Size XL (from 
July 2012). 
 
Perceval sutureless valve 
The Perceval valve is a surgical bioprosthetic heart valve comprising a 
biological component of bovine pericardium and an elastic Ni-Ti alloy stent 
made of two rings and 9 vertical struts covered by a thin coating of Carbofilm™ 
that improves biocompatibility (Fig. 1). The stent has the dual task of supporting 
the valve and holding it in place without any permanent suture. Thanks to its 
elastic properties, the stent adapts to the anatomy of the aorta and follows its 
movements, relieving the stress on the leaflets. The valve is collapsed with an 
atraumatic device compression, assuring that the valve leaflets are not affected. 
 
Surgical procedure 
The patients were operated either through a standard median sternotomy or 
upper mini-sternotomy. Anaesthetic and surgical techniques were standardized 
according to the preferences of each centre. A transverse aortotomy was 
performed about 0.5 cm distal to the sinu-tubular junction in order to leave a 
free edge for closure of the aortotomy after implantation of the device.  
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The native calcified aortic valve was excised and the aortic annulus decalcified. 
A regular annular profile was beneficial to ensure optimal sealing and 
preventing the risk of paraprosthetic leak. The sizing of the annulus was done 
with the dedicated sizers.  
For this series, the study valve was available in three sizes: Size S, to be 
implanted in annulus sizes from 19 to 21 mm, Size M to be implanted in annulus 
sizes from 21 to 23 mm, and Size L for patients with an annulus size from 23 to 
25 mm. 
The implantation technique included several steps as already described 
elsewhere [3, 4, 5]. 
 
Concomitant coronary artery bypass graft (CABG) procedures were additionally 
performed in patients with coronary artery disease. This was usually done 
during the time when the study valve was being collapsed to keep the aortic 
cross clamp time as short as possible. 
After closure of the aortotomy in the usual fashion, release of the aortic cross 
clamp and thorough de-airing, the valve functioning was investigated by 
transesophageal echocardiography in all patients. 
Following the procedure, the patients received anticoagulation treatment 
according to the standard protocol in use at each center for bioprostheses. 
 
Patients: 
From April 2007 to August 2012, a total of 765 patients were enrolled in these 
three Perceval studies (30 Pilot, 150 Pivotal and 585 Cavalier subjects). Out of 
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765 patients included in the study, the Perceval valve was implanted in 731 
patients (95.6%), while in 34 cases (4.4%), conversion to commercially 
available valves was required. 
The enrolment was carried out in a sequential, prospective manner such that all 
patients identified as candidates for standard aortic valve replacement with a 
bioprostheses (according to the practice of each centre) were offered the option 
of participating in the assessment if the they fulfilled the selection criteria 
defined in each protocol (Annex B).  
 
 
 
 
Follow-up 
According to the study protocol, clinical evaluation, ECG, blood exam and 
transthoracic echocardiographic examination were performed at discharge (or 
30 days), at 3-6 months, at 12 months and then annually up to 5 years. 
An Echo core laboratory performed a full analysis of the images and relevant 
calculations and an independent Clinical Events Committee reviewed and 
adjudicated the complications. 
Adverse events were reported according to current guidelines [6]. Kaplan-Meier 
survival curve is shown in figure 2. 
 
Statistical analysis 
Statistical analyses were performed on all patients successfully implanted with a 
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Perceval valve. Categorical variables are reported as absolute and relative 
frequencies. For continuous data, means and standard deviations were 
calculated. Cumulative survival and freedom from events were estimated using 
the Kaplan-Meier method, with 95% confidence intervals (95% CI). Statistical 
analyses were performed using SAS software (Release 9.2, by SAS Institute 
Inc., Cary, NC, USA). A p-value <0.05 was considered to be statistically 
significant. 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
Patient demographics and procedural outcomes 
The mean age of the 731 patients was 78.5±5.3 years (range, 62-92 years). 
43.1% of patients were ≥ 80 years old. The preoperative data are reported in 
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Table 1. The majority of patients presented with valve stenosis (509/69.6%) due 
to degenerative disease. Out of 731 patients, 542 patients (74.1%) underwent 
surgery via median sternotomy, whereas the remaining 189 patients (25.9%) 
underwent a minimally invasive surgical approach. Two hundred forty (32.8%) 
patients had concomitant procedures. In 192 (26.3%) patients, coronary artery 
bypass grafting was performed. Operative data are summarized in Table 2. 
Mean aortic cross-clamp times and Cardio-pulmonary bypass (CPB) times were 
30.8 min and 50.8 min respectively for isolated aortic valve replacement via 
median sternotomy and 37.6 min. and 64.4 min. for a minimally invasive 
approach (Table 3).  
 
 
 
Complications 
All-cause and cardiac early mortality were 3.4% (25/731) and 1.9% (14/731), 
respectively. Among the early cardiac deaths, 3 occurred in OR. One occurred 
during operation in a patient with very critical preoperative status; the patient 
underwent successful implant of the device that was then removed due to the 
presence of a previous endocarditic lesion and the patient did not survive the 
surgery due to myocardial failure. In second case, death was caused by an 
acute myocardial dysfunction, a third case was due to annulus rupture during 
traditional valve implantation following aortic regurgitation with the Perceval 
valve. All-cause and cardiac late mortality were 7% (51/731) and 1.4% (10/731), 
respectively. 
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Specific cause of early and late death is reported in Table 4.  
During the follow-up phase, 21 patients required explantation of the Perceval 
valve, 10 early (1.4%), and 11 late.  
 
Early explants 
One case was related to a perioperative bleeding from the aorta: the patient 
was immediately returned to the operating room and had the Perceval valve as 
well as aortic root replaced with a biological valved conduit. The bleeding was 
caused by an aortic tear below the right coronary ostium, due to extensive 
decalcification of the annulus.  
Two cases of early explants occurred at 2 and 4 days post-surgery and were 
likely due to mis-sizing leading to para or intra- prosthetic regurgitation; 3 cases 
occurred at 2, 3, and 7 days after surgery and were related to malpositioning 
and subsequent regurgitation; one Perceval was explanted at 12 days where a 
paravalvular leak (PVL) was caused by early endocarditis. One explant 
occurred at 13 days after surgery and was related to intra-valvular regurgitation 
in a patient with severe calcified aortic annulus requiring ascending aorta 
replacement. One explant occurred at 20 days after implant and was likely 
related to inappropriate sizing and positioning. A last case occurred at 30 days, 
secondary to deep valve positioning and consequent PVL.  
Late Explants: 
Among the 11 late explants (1.5%), 8 were due to endocarditis. An explant 
occurred at 122 days after surgery and was related to a shunt between aorta 
and right ventricle. This was initially diagnosed at discharge and considered not 
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haemodynamically significant, even though it later increased causing recurrent 
cardiac decompensation, pulmonary hypertension, and severe tricuspid 
regurgitation. One explant occurred around 19 months after surgery because of 
fibrous pannus overgrowth. One last late explant occurred at almost 2 years 
after implant and was due to a pseudo-aneurysm of the non-coronary sinus 
resulting in paravalvular regurgitation; the valve was replaced along with the 
ascending aorta.  
Table 5 reports the early and late complications. Major paravalvular leak 
occurred in the 1.4% (early) and 1% (late follow up), respectively. The incidence 
of early major stroke was 1.6%, while 6 cases of late stoke events (0.8%) were 
reported. Forty-four patients (6.0%) with no prior history of cardiac rhythm 
disorders experienced early AV block III. Neither valve thrombosis nor structural 
valve deterioration was detected. No cases of valve migration or dislodgement 
after surgery were reported. 
 
Clinical results: 
The functional status significantly improved along with in the haemodynamic 
performance in the majority of the population. A marked decrease in NYHA 
stage was observed with the majority of patients falling in class I-II during 
follow-up. The mean gradient was 10.3 mmHg at discharge/1 month, 8.9 mmHg 
at 3-6 months and 12 months, 8.8 mmHg at 2 years, and 7.7 mmHg and 7.8 
mmHg at 3 and 4 years, respectively. At 5 year follow up, the few data available 
at the time of the data analysis (6 echo exams) showed a mean gradient of 7.8 
mmHg. This gradient reduction was correlated to an increase in the effective 
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orifice area from 0.75 cm2 preoperatively to 1.49 cm2 at discharge/1 month, 
1.51 cm2 at 3-6 months, 1.55 cm2 at 12 months, up to 1.80 cm2 at 5 years, and 
to a LV-mass regression, which went from 254.5 g to 177.4 g at 3 years. 
Hemodynamic results by valve size are reported in Table 6. 
Discussion 
Aortic valve replacement has been widely accepted as the gold standard for the 
treatment of patients with aortic valve stenosis [7]. The mean age of the patients 
referred for AVR has been increasing along with the demographic changes. In 
the present study cohort more than 40% of the patients were 80 years or older. 
The 5-year outcomes from patients undergoing AVR with Perceval valve 
demonstrate that the device is safe and well performing, even in a old 
population with co morbidities. 
 
Previous studies demonstrated that the duration of aortic cross-clamping and 
CPB are independent predictors of survival after either aortic valve replacement 
or combined valve operations with CABG [8, 9]. Therefore, a new technology for 
shortening aortic cross-clamp time and consequently CPB time is mandatory to 
further reduce mortality after AVR surgery.  
 
The Perceval valve features a fairly high adaptability to different surgical 
approaches as showed by this study. The implantations were performed either 
via full sternotomy or minimally invasive approach (mini-sternotomy or right 
anterior mini-thoracotomy) [10, 11].  
Previous experiences showed that the use of less invasive AVR was associated 
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with excellent outcomes in terms of postoperative complications and hospital 
stay [12, 13]. However the reduced working space for the exposure and 
implantation of the prosthetic valves (especially in small or calcified aortic 
annuli) presented the drawback of the increasing surgical times. In such cases 
the adoption of sutureless technology may facilitate the less invasive AVR 
approach. In this study the low cross-clamp times, that were achieved with both 
surgical approaches, demonstrates the ease of implantation of the Perceval 
valve.  
 
The possibility of performing simultaneous procedures, in particular CABG, with 
this device represents an advantage as compared to other interventional 
techniques, such as trans-catheter aortic valve implantations (TAVI). This is 
important as according to the STS database, the proportion of candidates 
requiring concomitant CABG has risen from 5% to 25% over the past 20 years. 
Previous experience already demonstrated the safety and efficacy of the 
Perceval valve even in cases of concomitant cardiac procedures. [14].  
In patients requiring aortic valve replacement along with concomitant 
procedures, shortening the aortic cross clamp and CPB time may help reduce 
the mortality and morbidity. Ranucci et al. [9] reported that the aortic cross 
clamp time is an independent predictor of severe cardiovascular morbidity, with 
an increased risk of 1.4% per one minute increase. Therefore, the use of 
sutureless valves may help reduce the procedural times thanks to the absence 
of need for sutures.  
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The clinical results up to 5 years follow-up reported in this large cohort of 
patients, confirm the safety and efficacy of the Perceval sutureless aortic valve. 
Rates of early and late mortality and complications such as stroke, PVL are 
comparable with reported rates for traditional AVR [15,16]. Even in cases 
requiring explantation of the Perceval, the procedure was easy and the 
Perceval valve was removed without technical issues, as previously described 
[17]. 
New occurrences of early AV block III leading to pacemaker implant in patients 
with no prior history of cardiac rhythm disorders was 6.0%, which is within the 
ranges reported in literature for traditional AVR [18]. This rate could also be 
related to the initial learning curve effect. Additionally, the large number of 
centers in this cohort and variability of operators and protocols of rhythm 
disorders management could be considered as an additional potential 
contributing factor, considering that in one of the biggest cohort in experienced 
centers, the rate was lower (4.2%) [19]. 
No valve dislodgement or migration, thrombosis or structural valve deterioration 
was observed even after a follow-up of up to 5 years.  
The valve implantation resulted in significant improvement of patient’s 
symptoms. Even though a majority of patients were quite short in stature with 
small aortic annulus and received small size prostheses, the post-operative 
trans-valvular gradients were low and remained stable over time up to 5 years 
follow-up. In patients with a critically small annulus, this valve allows 
maximization of the bioprosthetic diameter, as previously reported [20]. The 
haemodynamic data show an improvement of the left ventricular function.  
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Conclusions 
In summary, this study reports the widest and longest experience with a 
sutureless valve and highlights its safety and efficacy also in an elderly 
population. The Perceval implant could be easily performed by offering a 
significant reduction of cross clamping and cardiopulmonary bypass times with 
respect to both the traditional valve prostheses and the other sutureless 
prostheses available on the market [21, 22, 23], even when performed via 
minimally invasive approach. Therefore, in patients needing aortic valve 
replacement with or without concomitant procedures, this device could have an 
advantage compared to conventional sutured valves. The continuation of the 
patient follow-up will provide further assessment of long-term valve 
performance. 
 
Limitation 
One limitation of this study is that there is no control group with patients 
receiving conventional valves to determine the Perceval additional benefits 
respect to the gold standard. Furthermore, EuroScore was used for the three 
studies even though EuroScore may overestimate risk of mortality. 
 
Disclosure: 
The participating centers received an unrestricted study grant from Sorin to 
conduct this study. The following authors are consultants/proctors for Sorin: M. 
Shrestha,  T. Fischlein, B. Meuris, M Misfeld and  F. Laborde. 
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Annex B Studies inclusion and exclusion criteria  
Inclusion Criteria Exclusion Criteria 
1. > 75 years (Pilot and Pivotal 
Trials), ≥ 65 years (CAVALIER 
Trial); 
1. Subjects involved in any other 
clinical study for drugs or devices 
2. Subjects with aortic valve stenosis 
or steno-insufficiency; 
2. Subjects with a previously 
implanted Perceval prosthesis, 
within the clinical study, that 
requires replacement 
3. Subjects in which preoperative 
evaluation indicated the need for 
native or prosthetic aortic valve 
replacement with a biological 
prosthesis; 
3. Subjects with previous implantation 
of valve prostheses or annuloplasty 
ring not being replaced by the study 
valve 
4. Subjects willing to sign the 
informed consent; 
4. Subjects requiring simultaneous 
cardiac procedures, apart from 
septal myectomy and/or coronary 
by-pass 
5. Subjects willing to undergo all the 
medical follow-ups and 
echocardiography examinations 
and laboratory tests that form part 
of this present protocol. 
5. Subjects who require double or 
multiple valve replacement or repair 
in whom the mitral, tricuspid, or 
pulmonic valve would be replaced 
with a non-Perceval valve or 
repaired 
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 6. Subjects with aneurysmal dilation 
or dissection of the ascending 
aortic wall 
 7. Subjects needing non elective 
intervention 
 8. Subjects with active endocarditis 
 9. Subjects with active myocarditis 
 10. Subjects with congenital bicuspid 
aortic valve 
 11. Subjects with aortic root 
enlargement, where the ratio 
between the diameter of the sino-
tubular junction and the annulus 
diameter, assessed by TTE, is > 
1.3  
 12. Subjects with aortic root height  
(measured from aortic annulus to 
sino-tubular junction) ≥ 21 mm for 
size S/21, ≥ 22.5 mm for size M/23, 
≥ 24 mm for size L/25  
 13. Subjects with myocardial infarction 
< 90 days before the planned valve 
implant surgery 
 14. Subjects with known 
27 
hypersensitivity to nickel alloys 
 15. Subjects involved in any other 
clinical study for drugs or devices 
 16. The subject is a prison inmate, 
institutionalized, or is unable to give 
informed consent; 
 17. The subject has a major or 
progressive non-cardiac disease 
that, in the investigator’s 
experience, results in a life 
expectancy of less than 1 year, or 
the implant of the device produces 
an unacceptable increased risk to 
the patient; 
 18. The subject is undergoing renal 
dialysis for chronic renal failure or 
has hyperparathyroidism; 
 19. The subject has an acute 
preoperative neurological deficit, 
myocardial infarction, or cardiac 
event that has not returned to 
baseline or stabilized ≥ 30 days 
prior to the planned valve implant 
surgery. 
28 
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Table 1:  Preoperative characteristics and risk factors (mean ± std).  
 
Patients N=731 % 
  Sex   
F 498 68.1 
M 233 31.9 
   
Mean age ± SD (range) 
78.5±5.3 (62.0-
92.0) 
 
Patients ≥ 80 years 315 43.1 
Mean Height ± SD (range) (cm) 162.9±7.9 (140.0-
186.0) 
 
Mean Weight ± SD (range) (Kg) 72.4±13.4 (38.0-
112.0) 
 
Mean BSA ± SD (range) 1.8 ± 0.2 (1.3 - 2.4)  
Risk Factorsa   
Systemic hypertension  589 80.6 
Diabetes  203 27.8 
Smokers  155 21.2 
Extracardiac arteriopathy  117 16.0 
Renal insufficiency  108 14.8 
Cerebrovascular disease  75 10.3 
Previous Cardiovascular Surgeryb   
30 
CABG 14 1.9 
Previous valve surgery 7 1.0 
CABG + previous valve surgery 1 0.4 
NYHA   
I 19 2.6 
II 163 22.3 
 III 488 66.8 
 IV 42 5.7 
   Not available 19 2.6 
Type of valve lesion    
 Stenosis 509 69.6 
 Steno-Insufficiency 221 30.2 
 Insufficiency 1 0.1 
Mean EuroScore ± SD (range) 
10.9 ± 8.2 (1.2 - 
75.3) 
 
Mean STS Score ± SD (range)  
8.5 ± 8.6 (0.8 - 
67.5) 
 
Rhythm disorders   
 Previous atrial fibrillation/flutter 88 12.0 
 Previous heart block 52 7.1 
a: Risk factors  patient could have more than 1 risk factor; b: Patient can have 
more than one previous surgery 
 
 
31 
 
Table 2: Operative data.  
 
Patients N=731 % 
 Surgical approach   
    Median sternotomy 542 74.1 
    Minimally invasive approach 189 25.9 
Aortic valve condition   
Tricuspid 714 97.7 
Bicuspid  8 1.1 
Other (7 previous bioprostheses, 1 pseudo 
bicuspid, 1 monocusp) 
9 1.2 
Valve Size   
S/21 122 16.7 
M/23 383 52.4 
L/25 226  30.9 
Concomitant Procedures a    
None 
Concomitant procedures 
491  
240  
67.2 
32.8 
CABGs 192  26.3 
Septal myectomy 27 3.7 
Other cardiac concomitant procedures 27 3.7 
Other non cardiac concomitant procedures 11 1.5 
32 
a  patients can have more than one procedure 
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Table 3: Procedure timings.  
 
 Isolated AVR 
(N=498) 
Concomitant 
cardiac 
procedure 
(N=233) 
OVERALL 
(N=731) 
 Mean (SD) Mean (SD) Mean (SD) 
Median 
sternotomy     
     CPB time  50.8 (19.5) 79.5 (33.3) 62.4 (29.5) 
     X-clamp time  30.8 (10.8) 51.5 (23.6) 39.2 (19.9) 
Minimally invasive  
   
     CPB time  64.4 (19.2) 68.5 (23.1) 64.7 (19.5) 
     X-clamp time  37.6 (12.0) 42.6 (13.7) 37.9 (12.1) 
Overall  
   
    CPB time  55.8 (20.5) 78.9 (32.9) 63.0 (27.2) 
    X-clamp time  33.3 (11.7) 51.0 (23.2) 38.8 (18.2) 
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Table 4: Specific causes of early (≤30 days) and late (> 30 days) deaths 
 
 Early N = 25 Late N = 51 
Cardiac N= 14 (days post-
op) 
N = 10 (days post-op) 
In OR 3  
Heart failure 2 (1, 4) 6 (40, 85, 105, 302, 395, 
902) 
Rhythm troubles 5 (0, 4, 6, 16, 23)  
Endocarditis 1 (13) 1 (264) 
Multiorgan failure 1 (11) 1 (191) 
Cardiac insufficiency 2 (19, 24)  
Sepsis  1 (685) 
Stroke  1 (58) 
Non cardiac N= 8 (days post-
op) 
N= 30 
Multiorgan failure 4 (7, 14, 29, 29) 4 (40, 45, 55, 101) 
Liver insufficiency 1 (4)  
Gastro-intestinal bleeding 1 (18)  
Neurological vascular 
accident  
1 (30)  
Sepsis leading to respiratory 
insufficiency and coma 
1 (30)  
Sepsis  2 (33, 43) 
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Infections  7 (33, 41, 55, 67, 154, 682, 
733) 
Renal failure  5 (181, 311, 329, 361, 432) 
Diarrhea and dehydratation  1 (60) 
Respiratory insufficicency  2 (37, 40) 
Neoplastic pathology  4 (49, 84, 220, 297) 
Autoimmune 
thrombocytopenia 
 1 (71) 
Accident  1 (76) 
Cerebral bleeding  1 (670) 
Cerebral hematoma due to 
fall 
 1 (204) 
Worsening of COPD  1 (170) 
Sudden, unexpected, 
unexplained 
N= 3 (13, 24, 28) N= 11 (34, 76, 82, 88, 152, 
165, 376, 443, 602, 1196, 
1267) 
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Table 5: Haemodynamic performance as evaluated by transthoracic echocardiography (Mean ± SD). 
 
 
Preoperative 
Discharge/1 
month 
3-6 
months 
12 
months 
2 years 3 years 4 years 5 years 
         
LVEF 
[%] 
60.1±11.6 58.4±11.2 60.7±9.9 61.4±9.9 67.0±8.5 67.0±9.0 66.1±9.1 65.8±7.7 
size 21 63.8±12.9 62.1±10.0 62.7±9.9 64.9±8.9 65.5±11.1 68.1±5.8 64.3±5.1 64.0±4.2 
size 23 61.9±11.1 60.6±10.7 62.7±9.6 63.2±8.6 67.9±7.5 66.4±10.8 67.0±10.9 67.0±10.1 
size 25 55.1±10.0 52.9±10.4 55.9±8.6 55.5±10.5 56.0 NA NA NA 
         
MPG 
[mmHg]  
42.9±16.4 10.3±4.4 8.9±4.3 8.9±4.7 8.8±3.9 7.7±2.8 7.8±3.8 8.8±4.6 
size 21 43.4±17.7 10.9±5.1 10.5±6.3 10.2±5.2 8.2±3.4 9.7±3.0 8.7±4.0 10.5±7.8 
37 
size 23 41.8±15.9 10.5±4.5 8.9±4.0 8.8±4.9 9.0±4.1 6.8±2.3 7.5±4.0 8.0±3.6 
size 25 44.7±16.6 9.5±3.8 8.0±3.2 8.2±3.7 7.8 NA NA NA 
         
PPG 
[mmHg]  
74.0±25.6 20.4±8.5 17.8±7.7 17.7±8.0 20.0±7.9 16.0±5.2 17.8±8.1 21.1±9.7 
size 21 78.8±27.9 22.6±10.6 21.0±9.0 20.7±9.7 19.4±5.7 19.0±4.5 20.6±9.3 27.0±15.5 
size 23 72.5±24.6 21.1±8.4 18.3±7.8 17.6±7.8 20.3±8.5 14.6±5.0 16.7±8.0 18.2±6.4 
size 25 73.6±25.7 17.9±6.5 15.1±5.5 15.8±6.3 14.3 NA NA NA 
         
EOA 
[cm2] 
0.75±0.23 1.49±0.39 1.51±0.37 1.55±0.37 1.70±0.46 1.64±0.42 1.68±0.43 1.80±0.30 
size 21 0.75±0.27 1.40±0.37 1.40±0.37 1.47±0.37 1.71±0.49 1.44±0.22 1.40±0.30 1.55±0.09 
size 23 0.76±0.23 1.52±0.41 1.51±0.38 1.56±0.40 1.71±0.46 1.74±0.46 1.79±0.44 1.92±0.30 
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size 25 0.73±0.19 1.49±0.35 1.56±0.37 1.57±0.31 1.19 NA NA NA 
         
LVMASS 
[g] 
254.5±77.6 238.6±74.3 216.2±66.5 216.6±70.6 188.6±66.1 177.4±46.9 116.0±12.7 227.7±74.3 
size 21 224.0±64.4 190.0±63.0 169.9±49.5 180.7±59.6 142.0±80.6 174.2±57.3 107.0 266.5±44.5 
size 23 253.7±79.2 233.8±70.8 214.3±65.7 212.8±68.5 185.4±54.3 179.1±43.9 125.0 150.0 
size 25 269.5±77.1 262.6±73.7 241.8±62.8 242.5±70.6 316.0 NA NA NA 
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Table 6: Observed postoperative adverse events rates. All patients, n=731. 
Cumulative follow-up = 729 pts-yr  
 
 
Total 
Early events 
(≤30 days) 
Late events 
(>30 days) 
n % n % n % %/pts-yr  
41 
Deaths 76 10.4 25 3.4 51 7.0 7.0 (5.4-8.6) 
 Cardiac  24 2.1 14 1.9 10 1.4 1.4 (1.2-1.6) 
 Non-
cardiac  
38 5.2 8 1.1 30 4.1 4.1 (2.9-5.3) 
 Sudden, 
Unexpected, 
Unexplained 
Death/Unknown 
14 1.9 3 0.4 11 1.5 1.5 (0.8-2.2) 
Explants 21 2.9 10 1.4 11 1.5 1.5 (0.8-2.2) 
Stroke 18 2.5 12 1.6 6 0.8 0.8 (0.3-1.3) 
Intra-
prosthetic 
regurgitation 
5 0.7 4 0.6 1 0.1 0.1 
(0.0-
0.3) 
       Minor  2 0.3 2 0.3 0 0.0 0.0 - 
       Major  3 0.4 2 0.3 1 0.1 0.1 (0.0-0.3) 
Paravalvular 
leak 
19 2.6 10 1.4 9 1.2 1.2 
(0.6-
1.9) 
       Minor  2 0.3 0 0.0 2 0.3 0.3 (0.0-0.6) 
       Major  17 2.3 10 1.4 7 1.0 1.0 (0.4-1.6) 
Endocarditis 14 1.9 2 0.3 12 1.6 1.7 (0.9-2.4) 
AV block III 79 10.8 65 8.9 14 1.9 1.9 (1.1-2.8) 
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        AV block III in 
patients without 
preoperative cardiac 
rhythm 
abnormalities 
54 7.4 44 6.0 10 1.4 1.4 (1.2-1.6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure Legend: 
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1. Figure 1: Perceval valve. 
2. Figure 2: Kaplan- Meier Survival curve. 
